全体要約
2023年の特発性肺線維症の治療市場は、1854.6百万米ドルと評価され、2030年には3070.7百万米ドルに達する見込みで、年平均成長率は7.5%です。市場の成長には、製品の差別化やコスト削減、サプライチェーンの最適化が重要です。企業は研究開発に投資し、戦略的パートナーシップを結ぶ必要があります。
特発性肺線維症の治療は、肺の組織が硬くなる病気に対する治療法です。市場は、薬剤クラス、酸素療法、肺移植などのタイプに分かれ、病院やクリニックでの利用が見込まれています。市場の成長を促進する要因には、政府の規制や技術革新、消費者の嗜好の変化が含まれます。
関連する質問
1854.6百万USD（2023年）
7.5%（2023年から2030年）
バイオジェン, ボーリンガー・インゲルハイム, ブリストル・マイヤーズ スクイブ, シプラ, ホフマン・ラ・ロシュ, ファイブロゲン, ガラパゴス, メディシノバ, メルク, ノバルティス, プロメティック・ライフ・サイエンシズ
製品の差別化, コスト削減, サプライチェーンの最適化
概要
この研究報告は、世界の特発性肺線維症治療市場の成長可能性を強調しています。特発性肺線維症治療は、今後の市場で安定した成長を示すと予想されています。しかし、製品の差別化、コスト削減、サプライチェーンの最適化は、特発性肺線維症治療の広範な採用にとって依然として重要です。市場プレーヤーは、特発性肺線維症治療市場が提供する膨大な機会を活かすために、研究開発に投資し、戦略的パートナーシップを築き、進化する消費者の嗜好に合わせた提供を行う必要があります。
特発性肺線維症治療は、肺の組織が硬くなる原因となる肺疾患に対する治療です。
2022年の世界の医薬品市場は1475億USDで、今後6年間にわたって5％のCAGRで成長すると予測されています。医薬品市場には化学薬品と生物学的薬品が含まれます。生物学的製剤は2022年に381億USDになると予想されており、対照的に化学薬品市場は2018年の1005億USDから2022年には1094億USDに増加すると見積もられています。医薬品市場には、医療に対する需要の増加、技術革新、慢性疾患の蔓延、医薬品製造セグメントの開発に対する民間および政府機関からの資金提供の増加、薬の研究開発活動の増加などの要因が存在します。しかし、業界は厳しい規制、高い研究開発コスト、特許の失効などの課題にも直面しています。企業は競争力を維持し、製品が必要な患者に届くようにするために、常に革新を続け、これらの課題に適応する必要があります。さらに、COVID-19パンデミックはワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬会社が新たな公衆衛生のニーズに迅速かつ柔軟に対応する必要性をさらに強調しました。
主要な特徴：
特発性肺線維症治療市場に関する報告書は、さまざまな側面を反映し、業界に対する貴重な洞察を提供します。
市場規模と成長：この調査報告書は特発性肺線維症治療市場の現在の規模と成長についての概要を提供します。歴史的データ、タイプによる市場セグメンテーション（例：薬剤クラス、酸素療法）、および地域別の内訳が含まれる場合があります。
市場の推進要因と課題：レポートは、特発性肺線維症治療市場の成長を促進する要因を特定し分析することができます。これには、政府の規制、環境問題、技術の進歩、消費者の嗜好の変化などが含まれます。また、インフラの制約、レンジ不安、高い初期コストなど、業界が直面している課題も強調することができます。
競争環境：この調査報告書は、特発性肺線維症治療市場における競争環境の分析を提供します。主要なプレーヤーのプロフィール、市場シェア、戦略、および製品提供が含まれています。また、新興プレーヤーとその市場への潜在的な影響についても強調することができます。
技術の進展：この研究報告書では、特発性肺線維症治療産業における最新の技術の進展について詳しく掘り下げることができます。特発性肺線維症治療技術の進歩、特発性肺線維症治療の新規参入者、特発性肺線維症治療の新しい投資、および特発性肺線維症治療の未来を形作るその他の革新が含まれます。
下流傾向: このレポートは、特発性肺線維症治療市場における顧客の購買行動や採用動向に関する洞察を提供できます。特発性肺線維症治療製品に対する顧客の購買決定に影響を与える要因や好みが含まれています。
政府の政策とインセンティブ：この調査報告書は、特発性肺線維症治療市場に対する政府の政策とインセンティブの影響を分析しています。これには、規制の枠組み、助成金、税のインセンティブ、および特発性肺線維症治療市場を促進することを目的としたその他の措置の評価が含まれる場合があります。また、報告書は市場成長を促進する上でのこれらの政策の効果も評価しています。
環境影響と持続可能性：リサーチレポートは、特発性肺線維症治療市場の環境影響と持続可能性の側面を評価しています。
市場予測と将来の展望：実施された分析に基づき、研究報告書は特発性肺線維症治療産業の市場予測と展望を提供します。これには、市場規模、成長率、地域の動向、技術的進展および政策の発展に関する予測が含まれます。
推奨事項と機会：報告書は、業界のステークホルダー、政策立案者、投資家への推奨事項で締めくくられています。新たなトレンドを活用し、課題を克服し、特発性肺線維症治療市場の成長と発展に寄与するための市場参加者に対する潜在的な機会が強調されています。
市場セグメンテーション：
特発性肺線維症治療市場は、タイプおよびアプリケーションによって分割されています。2019年から2030年の期間において、セグメント間の成長は、タイプ別およびアプリケーション別の消費価値に関する正確な計算と予測を提供します。
タイプ別セグメンテーション
薬剤クラス
酸素療法
肺移植
その他
用途別セグメンテーション
病院
クリニック
このレポートは地域別に市場を分割しています：
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中東とアフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下に紹介する企業は、一次専門家から収集した情報と、企業のカバレッジ、製品ポートフォリオ、市場浸透率を分析した結果に基づいて選定されています。
バイオジェン
ボーリンゲルインゲルハイム社
ブリストル・マイヤーズ スクイブ会社
シプラ
ホフマン・ラ・ロシュ株式会社
フィブロジェン社
ガラパゴスNV
メディシノバ社
メルク社
ノバルティス AG
プロメティックライフサイエンス社
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルの特発性肺線維症の治療市場規模、（2019年～2030年）
2.1.2 特発性肺線維症の治療市場規模、CAGR（地域別）（2019年 vs 2023年 vs 2030年）
2.2 特発性肺線維症の治療セグメント、タイプ別
2.2.1 薬品クラス
2.2.2 酸素療法
2.2.3 肺移植
2.2.4 その他
2.3 特発性肺線維症の治療市場規模：タイプ別
2.3.1 特発性肺線維症の治療市場規模、CAGR（タイプ別）（2019年 vs 2023年 vs 2030年）
2.3.2 グローバルの特発性肺線維症の治療市場規模、市場シェア（タイプ別）（2019年～2024年）
2.4 特発性肺線維症の治療セグメント、用途別
2.4.1 病院
2.4.2 クリニック
2.5 特発性肺線維症の治療市場規模：用途別
2.5.1 特発性肺線維症の治療市場規模、CAGR（用途別）（2019年 vs 2023年 vs 2030年）
2.5.2 グローバルの特発性肺線維症の治療市場規模、市場シェア（用途別）（2019年～2024年）
3 特発性肺線維症の治療市場規模：プレイヤー別
3.1 特発性肺線維症の治療市場規模、市場シェア（プレイヤー別）
3.1.1 グローバルにおける特発性肺線維症の治療市場の収益規模、プレイヤー別（2019年～2024年）
3.1.2 グローバルにおける特発性肺線維症の治療市場の収益シェア、プレイヤー別（2019年～2024年）
3.2 グローバルの特発性肺線維症の治療市場キープレイヤー拠点および提供製品
3.3 市場集中度分析
3.3.1 競合情勢分析
3.3.2 集中度レシオ（CR3、CR5、CR10）（2022年～2024年）
3.4 新製品・潜在的参入
3.5 M&A、拡大
4 特発性肺線維症の治療、地域別
4.1 特発性肺線維症の治療市場規模（地域別）（2019年～2024年）
4.2 アメリカズにおける特発性肺線維症の治療市場規模成長（2019年〜2024年）
4.3 APACにおける特発性肺線維症の治療市場規模成長（2019年〜2024年）
4.4 ヨーロッパにおける特発性肺線維症の治療市場規模成長（2019年〜2024年）
4.5 中東・アフリカにおける特発性肺線維症の治療市場規模成長（2019年〜2024年）
5 アメリカズ
5.1 アメリカズにおける特発性肺線維症の治療市場規模、国別（2019年〜2024年）
5.2 アメリカズにおける特発性肺線維症の治療市場規模、タイプ別（2019年〜2024年）
5.3 アメリカズにおける特発性肺線維症の治療市場規模、用途別（2019年〜2024年）
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおける特発性肺線維症の治療市場規模、地域別（2019年〜2024年）
6.2 APACにおける特発性肺線維症の治療市場規模、タイプ別（2019年〜2024年）
6.3 APACにおける特発性肺線維症の治療市場規模、用途別（2019年〜2024年）
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
7 ヨーロッパ
7.1 ヨーロッパの特発性肺線維症の治療 国別（2019年～2024年）
7.2 ヨーロッパにおける特発性肺線維症の治療市場規模、タイプ別（2019年〜2024年）
7.3 ヨーロッパにおける特発性肺線維症の治療市場規模、用途別（2019年〜2024年）
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカの特発性肺線維症の治療 地域別（2019年～2024年）
8.2 中東・アフリカにおける特発性肺線維症の治療市場規模、タイプ別（2019年〜2024年）
8.3 中東・アフリカにおける特発性肺線維症の治療市場規模、用途別（2019年〜2024年）
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 グローバルの特発性肺線維症の治療市場、市場予測
10.1 グローバルの特発性肺線維症の治療、市場予測（地域別）（2025年～2030年）
10.1.1 グローバルの特発性肺線維症の治療、市場予測（地域別）（2025年～2030年）
10.1.2 アメリカズの特発性肺線維症の治療、市場予測
10.1.3 APACの特発性肺線維症の治療、市場予測
10.1.4 ヨーロッパの特発性肺線維症の治療、市場予測
10.1.5 中東・アフリカの特発性肺線維症の治療、市場予測
10.2 アメリカズの特発性肺線維症の治療、市場予測（国別）（2025年～2030年）
10.3 APACの特発性肺線維症の治療、市場予測（地域別）（2025年～2030年）
10.4 ヨーロッパの特発性肺線維症の治療、市場予測（国別）（2025年～2030年）
10.5 中東・アフリカの特発性肺線維症の治療、市場予測（地域別）（2025年～2030年）
10.6 グローバルの特発性肺線維症の治療、市場予測（タイプ別）（2025年～2030年）
10.7 グローバルの特発性肺線維症の治療、市場予測（用途別）（2025年～2030年）
11 キープレイヤー分析
11.1 Biogen
11.1.1 Biogen：企業情報
11.1.2 Biogen：特発性肺線維症の治療分野の提供製品
11.1.3 Biogen：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.1.4 Biogen：主要事業概要
11.1.5 Biogen：直近の展開
11.2 Boehringer Ingelheim GMBH
11.2.1 Boehringer Ingelheim GMBH：企業情報
11.2.2 Boehringer Ingelheim GMBH：特発性肺線維症の治療分野の提供製品
11.2.3 Boehringer Ingelheim GMBH：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.2.4 Boehringer Ingelheim GMBH：主要事業概要
11.2.5 Boehringer Ingelheim GMBH：直近の展開
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company：企業情報
11.3.2 Bristol-Myers Squibb Company：特発性肺線維症の治療分野の提供製品
11.3.3 Bristol-Myers Squibb Company：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.3.4 Bristol-Myers Squibb Company：主要事業概要
11.3.5 Bristol-Myers Squibb Company：直近の展開
11.4 Cipla
11.4.1 Cipla：企業情報
11.4.2 Cipla：特発性肺線維症の治療分野の提供製品
11.4.3 Cipla：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.4.4 Cipla：主要事業概要
11.4.5 Cipla：直近の展開
11.5 Hoffmann-La Roche AG
11.5.1 Hoffmann-La Roche AG：企業情報
11.5.2 Hoffmann-La Roche AG：特発性肺線維症の治療分野の提供製品
11.5.3 Hoffmann-La Roche AG：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.5.4 Hoffmann-La Roche AG：主要事業概要
11.5.5 Hoffmann-La Roche AG：直近の展開
11.6 Fibrogen, Inc
11.7 Galapagos NV
11.7.1 Galapagos NV：企業情報
11.7.2 Galapagos NV：特発性肺線維症の治療分野の提供製品
11.7.3 Galapagos NV：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.7.4 Galapagos NV：主要事業概要
11.7.5 Galapagos NV：直近の展開
11.8 Medicinova, Inc
11.9 Merck & Co\., Inc
11.10 Novartis AG
11.10.1 Novartis AG：企業情報
11.10.2 Novartis AG：特発性肺線維症の治療分野の提供製品
11.10.3 Novartis AG：特発性肺線維症の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.10.4 Novartis AG：主要事業概要
11.10.5 Novartis AG：直近の展開
11.11 Prometic Life Sciences Inc
12 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
The research report highlights the growth potential of the global Idiopathic Pulmonary Fibrosis Treatment market. Idiopathic Pulmonary Fibrosis Treatment are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Idiopathic Pulmonary Fibrosis Treatment. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Idiopathic Pulmonary Fibrosis Treatment market.
Idiopathic Pulmonary Fibrosis Treatment is treatment work on a lung disease which causes the tissue in your lungs to become stiff.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Idiopathic Pulmonary Fibrosis Treatment market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Idiopathic Pulmonary Fibrosis Treatment market. It may include historical data, market segmentation by Type (e.g., Drug Class, Oxygen Therapy), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Idiopathic Pulmonary Fibrosis Treatment market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Idiopathic Pulmonary Fibrosis Treatment market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Idiopathic Pulmonary Fibrosis Treatment industry. This include advancements in Idiopathic Pulmonary Fibrosis Treatment technology, Idiopathic Pulmonary Fibrosis Treatment new entrants, Idiopathic Pulmonary Fibrosis Treatment new investment, and other innovations that are shaping the future of Idiopathic Pulmonary Fibrosis Treatment.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Idiopathic Pulmonary Fibrosis Treatment market. It includes factors influencing customer ' purchasing decisions, preferences for Idiopathic Pulmonary Fibrosis Treatment product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Idiopathic Pulmonary Fibrosis Treatment market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Idiopathic Pulmonary Fibrosis Treatment market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Idiopathic Pulmonary Fibrosis Treatment market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Idiopathic Pulmonary Fibrosis Treatment industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Idiopathic Pulmonary Fibrosis Treatment market.
Market Segmentation:
Idiopathic Pulmonary Fibrosis Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Drug Class
Oxygen Therapy
Lung Transplant
Others
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biogen
Boehringer Ingelheim GMBH
Bristol-Myers Squibb Company
Cipla
Hoffmann-La Roche AG
Fibrogen, Inc.
Galapagos NV
Medicinova, Inc.
Merck & Co., Inc.
Novartis AG
Prometic Life Sciences Inc.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Idiopathic Pulmonary Fibrosis Treatment Market Size 2019-2030
2.1.2 Idiopathic Pulmonary Fibrosis Treatment Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Idiopathic Pulmonary Fibrosis Treatment Segment by Type
2.2.1 Drug Class
2.2.2 Oxygen Therapy
2.2.3 Lung Transplant
2.2.4 Others
2.3 Idiopathic Pulmonary Fibrosis Treatment Market Size by Type
2.3.1 Idiopathic Pulmonary Fibrosis Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Type (2019-2024)
2.4 Idiopathic Pulmonary Fibrosis Treatment Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Idiopathic Pulmonary Fibrosis Treatment Market Size by Application
2.5.1 Idiopathic Pulmonary Fibrosis Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Application (2019-2024)
3 Idiopathic Pulmonary Fibrosis Treatment Market Size by Player
3.1 Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Players
3.1.1 Global Idiopathic Pulmonary Fibrosis Treatment Revenue by Players (2019-2024)
3.1.2 Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Idiopathic Pulmonary Fibrosis Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Idiopathic Pulmonary Fibrosis Treatment by Regions
4.1 Idiopathic Pulmonary Fibrosis Treatment Market Size by Regions (2019-2024)
4.2 Americas Idiopathic Pulmonary Fibrosis Treatment Market Size Growth (2019-2024)
4.3 APAC Idiopathic Pulmonary Fibrosis Treatment Market Size Growth (2019-2024)
4.4 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size Growth (2019-2024)
4.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size Growth (2019-2024)
5 Americas
5.1 Americas Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2019-2024)
5.2 Americas Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2019-2024)
5.3 Americas Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Idiopathic Pulmonary Fibrosis Treatment Market Size by Region (2019-2024)
6.2 APAC Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2019-2024)
6.3 APAC Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Idiopathic Pulmonary Fibrosis Treatment by Country (2019-2024)
7.2 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2019-2024)
7.3 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment by Region (2019-2024)
8.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2019-2024)
8.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.1 Global Idiopathic Pulmonary Fibrosis Treatment Forecast by Regions (2025-2030)
10.1.1 Global Idiopathic Pulmonary Fibrosis Treatment Forecast by Regions (2025-2030)
10.1.2 Americas Idiopathic Pulmonary Fibrosis Treatment Forecast
10.1.3 APAC Idiopathic Pulmonary Fibrosis Treatment Forecast
10.1.4 Europe Idiopathic Pulmonary Fibrosis Treatment Forecast
10.1.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Forecast
10.2 Americas Idiopathic Pulmonary Fibrosis Treatment Forecast by Country (2025-2030)
10.2.1 United States Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.2.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.2.3 Mexico Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.2.4 Brazil Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.3 APAC Idiopathic Pulmonary Fibrosis Treatment Forecast by Region (2025-2030)
10.3.1 China Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.3.2 Japan Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.3.3 Korea Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.3.4 Southeast Asia Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.3.5 India Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.3.6 Australia Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.4 Europe Idiopathic Pulmonary Fibrosis Treatment Forecast by Country (2025-2030)
10.4.1 Germany Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.4.2 France Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.4.3 UK Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.4.4 Italy Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.4.5 Russia Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Forecast by Region (2025-2030)
10.5.1 Egypt Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.5.2 South Africa Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.5.3 Israel Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.5.4 Turkey Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.5.5 GCC Countries Idiopathic Pulmonary Fibrosis Treatment Market Forecast
10.6 Global Idiopathic Pulmonary Fibrosis Treatment Forecast by Type (2025-2030)
10.7 Global Idiopathic Pulmonary Fibrosis Treatment Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Biogen
11.1.1 Biogen Company Information
11.1.2 Biogen Idiopathic Pulmonary Fibrosis Treatment Product Offered
11.1.3 Biogen Idiopathic Pulmonary Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Biogen Main Business Overview
11.1.5 Biogen Latest Developments
11.2 Boehringer Ingelheim GMBH
11.2.1 Boehringer Ingelheim GMBH Company Information
11.2.2 Boehringer Ingelheim GMBH Idiopathic Pulmonary Fibrosis Treatment Product Offered
11.2.3 Boehringer Ingelheim GMBH Idiopathic Pulmonary Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Boehringer Ingelheim GMBH Main Business Overview
11.2.5 Boehringer Ingelheim GMBH Latest Developments
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Information
11.3.2 Bristol-Myers Squibb Company Idiopathic Pulmonary Fibrosis Treatment Product Offered
11.3.3 Bristol-Myers Squibb Company Idiopathic Pulmonary Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Bristol-Myers Squibb Company Main Business Overview
11.3.5 Bristol-Myers Squibb Company Latest Developments
11.4 Cipla
11.4.1 Cipla Company Information
11.4.2 Cipla Idiopathic Pulmonary Fibrosis Treatment Product Offered
11.4.3 Cipla Idiopathic Pulmonary Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Cipla Main Business Overview
11.4.5 Cipla Latest Developments
11.5 Hoffmann-La Roche AG
11.5.1 Hoffmann-La Roche AG Company Information
11.5.2 Hoffmann-La Roche AG Idiopathic Pulmonary Fibrosis Treatment Product Offered
11.5.3 Hoffmann-La Roche AG Idiopathic Pulmonary Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Hoffmann-La Roche AG Main Business Overview
11.5.5 Hoffmann-La Roche AG Latest Developments
11.6 Fibrogen, Inc.
11.6.1 Fibrogen, Inc. Company Information
11.6.2 Fibrogen, Inc. Idiopathic Pulmonary Fibrosis Treatment Product Offered
11.6.3 Fibrogen, Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Fibrogen, Inc. Main Business Overview
11.6.5 Fibrogen, Inc. Latest Developments
11.7 Galapagos NV
11.7.1 Galapagos NV Company Information
11.7.2 Galapagos NV Idiopathic Pulmonary Fibrosis Treatment Product Offered
11.7.3 Galapagos NV Idiopathic Pulmonary Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Galapagos NV Main Business Overview
11.7.5 Galapagos NV Latest Developments
11.8 Medicinova, Inc.
11.8.1 Medicinova, Inc. Company Information
11.8.2 Medicinova, Inc. Idiopathic Pulmonary Fibrosis Treatment Product Offered
11.8.3 Medicinova, Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Medicinova, Inc. Main Business Overview
11.8.5 Medicinova, Inc. Latest Developments
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Information
11.9.2 Merck & Co., Inc. Idiopathic Pulmonary Fibrosis Treatment Product Offered
11.9.3 Merck & Co., Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Merck & Co., Inc. Main Business Overview
11.9.5 Merck & Co., Inc. Latest Developments
11.10 Novartis AG
11.10.1 Novartis AG Company Information
11.10.2 Novartis AG Idiopathic Pulmonary Fibrosis Treatment Product Offered
11.10.3 Novartis AG Idiopathic Pulmonary Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Novartis AG Main Business Overview
11.10.5 Novartis AG Latest Developments
11.11 Prometic Life Sciences Inc.
11.11.1 Prometic Life Sciences Inc. Company Information
11.11.2 Prometic Life Sciences Inc. Idiopathic Pulmonary Fibrosis Treatment Product Offered
11.11.3 Prometic Life Sciences Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Prometic Life Sciences Inc. Main Business Overview
11.11.5 Prometic Life Sciences Inc. Latest Developments
12 Research Findings and Conclusion
List of Tables Table 1. Idiopathic Pulmonary Fibrosis Treatment Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions) Table 2. Major Players of Drug Class Table 3. Major Players of Oxygen Therapy Table 4. Major Players of Lung Transplant Table 5. Major Players of Others Table 6. Idiopathic Pulmonary Fibrosis Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions) Table 7. Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2019-2024) & ($ Millions) Table 8. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Type (2019-2024) Table 9. Idiopathic Pulmonary Fibrosis Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions) Table 10. Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2019-2024) & ($ Millions) Table 11. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Application (2019-2024) Table 12. Global Idiopathic Pulmonary Fibrosis Treatment Revenue by Players (2019-2024) & ($ Millions) Table 13. Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share by Player (2019-2024) Table 14. Idiopathic Pulmonary Fibrosis Treatment Key Players Head office and Products Offered Table 15. Idiopathic Pulmonary Fibrosis Treatment Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) Table 16. New Products and Potential Entrants Table 17. Mergers & Acquisitions, Expansion Table 18. Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Regions 2019-2024 & ($ Millions) Table 19. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Regions (2019-2024) Table 20. Global Idiopathic Pulmonary Fibrosis Treatment Revenue by Country/Region (2019-2024) & ($ millions) Table 21. Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share by Country/Region (2019-2024) Table 22. Americas Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2019-2024) & ($ Millions) Table 23. Americas Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Country (2019-2024) Table 24. Americas Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2019-2024) & ($ Millions) Table 25. Americas Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Type (2019-2024) Table 26. Americas Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2019-2024) & ($ Millions) Table 27. Americas Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Application (2019-2024) Table 28. APAC Idiopathic Pulmonary Fibrosis Treatment Market Size by Region (2019-2024) & ($ Millions) Table 29. APAC Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Region (2019-2024) Table 30. APAC Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2019-2024) & ($ Millions) Table 31. APAC Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Type (2019-2024) Table 32. APAC Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2019-2024) & ($ Millions) Table 33. APAC Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Application (2019-2024) Table 34. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2019-2024) & ($ Millions) Table 35. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Country (2019-2024) Table 36. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2019-2024) & ($ Millions) Table 37. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Type (2019-2024) Table 38. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2019-2024) & ($ Millions) Table 39. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Application (2019-2024) Table 40. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Region (2019-2024) & ($ Millions) Table 41. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Region (2019-2024) Table 42. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2019-2024) & ($ Millions) Table 43. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Type (2019-2024) Table 44. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2019-2024) & ($ Millions) Table 45. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Application (2019-2024) Table 46. Key Market Drivers & Growth Opportunities of Idiopathic Pulmonary Fibrosis Treatment Table 47. Key Market Challenges & Risks of Idiopathic Pulmonary Fibrosis Treatment Table 48. Key Industry Trends of Idiopathic Pulmonary Fibrosis Treatment Table 49. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Forecast by Regions (2025-2030) & ($ Millions) Table 50. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share Forecast by Regions (2025-2030) Table 51. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Forecast by Type (2025-2030) & ($ Millions) Table 52. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Forecast by Application (2025-2030) & ($ Millions) Table 53. Biogen Details, Company Type, Idiopathic Pulmonary Fibrosis Treatment Area Served and Its Competitors Table 54. Biogen Idiopathic Pulmonary Fibrosis Treatment Product Offered Table 55. Biogen Idiopathic Pulmonary Fibrosis Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 56. Biogen Main Business Table 57. Biogen Latest Developments Table 58. Boehringer Ingelheim GMBH Details, Company Type, Idiopathic Pulmonary Fibrosis Treatment Area Served and Its Competitors Table 59. Boehringer Ingelheim GMBH Idiopathic Pulmonary Fibrosis Treatment Product Offered Table 60. Boehringer Ingelheim GMBH Main Business Table 61. Boehringer Ingelheim GMBH Idiopathic Pulmonary Fibrosis Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 62. Boehringer Ingelheim GMBH Latest Developments Table 63. Bristol-Myers Squibb Company Details, Company Type, Idiopathic Pulmonary Fibrosis Treatment Area Served and Its Competitors Table 64. Bristol-Myers Squibb Company Idiopathic Pulmonary Fibrosis Treatment Product Offered Table 65. Bristol-Myers Squibb Company Main Business Table 66. Bristol-Myers Squibb Company Idiopathic Pulmonary Fibrosis Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 67. Bristol-Myers Squibb Company Latest Developments Table 68. Cipla Details, Company Type, Idiopathic Pulmonary Fibrosis Treatment Area Served and Its Competitors Table 69. Cipla Idiopathic Pulmonary Fibrosis Treatment Product Offered Table 70. Cipla Main Business Table 71. Cipla Idiopathic Pulmonary Fibrosis Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 72. Cipla Latest Developments Table 73. Hoffmann-La Roche AG Details, Company Type, Idiopathic Pulmonary Fibrosis Treatment Area Served and Its Competitors Table 74. Hoffmann-La Roche AG Idiopathic Pulmonary Fibrosis Treatment Product Offered Table 75. Hoffmann-La Roche AG Main Business Table 76. Hoffmann-La Roche AG Idiopathic Pulmonary Fibrosis Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 77. Hoffmann-La Roche AG Latest Developments Table 78. Fibrogen, Inc. Details, Company Type, Idiopathic Pulmonary Fibrosis Treatment Area Served and Its Competitors Table 79. Fibrogen, Inc. Idiopathic Pulmonary Fibrosis Treatment Product Offered Table 80. Fibrogen, Inc. Main Business Table 81. Fibrogen, Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 82. Fibrogen, Inc. Latest Developments Table 83. Galapagos NV Details, Company Type, Idiopathic Pulmonary Fibrosis Treatment Area Served and Its Competitors Table 84. Galapagos NV Idiopathic Pulmonary Fibrosis Treatment Product Offered Table 85. Galapagos NV Main Business Table 86. Galapagos NV Idiopathic Pulmonary Fibrosis Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 87. Galapagos NV Latest Developments Table 88. Medicinova, Inc. Details, Company Type, Idiopathic Pulmonary Fibrosis Treatment Area Served and Its Competitors Table 89. Medicinova, Inc. Idiopathic Pulmonary Fibrosis Treatment Product Offered Table 90. Medicinova, Inc. Main Business Table 91. Medicinova, Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 92. Medicinova, Inc. Latest Developments Table 93. Merck & Co., Inc. Details, Company Type, Idiopathic Pulmonary Fibrosis Treatment Area Served and Its Competitors Table 94. Merck & Co., Inc. Idiopathic Pulmonary Fibrosis Treatment Product Offered Table 95. Merck & Co., Inc. Main Business Table 96. Merck & Co., Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 97. Merck & Co., Inc. Latest Developments Table 98. Novartis AG Details, Company Type, Idiopathic Pulmonary Fibrosis Treatment Area Served and Its Competitors Table 99. Novartis AG Idiopathic Pulmonary Fibrosis Treatment Product Offered Table 100. Novartis AG Main Business Table 101. Novartis AG Idiopathic Pulmonary Fibrosis Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 102. Novartis AG Latest Developments Table 103. Prometic Life Sciences Inc. Details, Company Type, Idiopathic Pulmonary Fibrosis Treatment Area Served and Its Competitors Table 104. Prometic Life Sciences Inc. Idiopathic Pulmonary Fibrosis Treatment Product Offered Table 105. Prometic Life Sciences Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 106. Prometic Life Sciences Inc. Main Business Table 107. Prometic Life Sciences Inc. Latest Developments List of Figures Figure 1. Idiopathic Pulmonary Fibrosis Treatment Report Years Considered Figure 2. Research Objectives Figure 3. Research Methodology Figure 4. Research Process and Data Source Figure 5. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Growth Rate 2019-2030 ($ Millions) Figure 6. Idiopathic Pulmonary Fibrosis Treatment Sales by Geographic Region (2019, 2023 & 2030) & ($ millions) Figure 7. Idiopathic Pulmonary Fibrosis Treatment Sales Market Share by Country/Region (2023) Figure 8. Idiopathic Pulmonary Fibrosis Treatment Sales Market Share by Country/Region (2019, 2023 & 2030) Figure 9. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Type in 2023 Figure 10. Idiopathic Pulmonary Fibrosis Treatment in Hospital Figure 11. Global Idiopathic Pulmonary Fibrosis Treatment Market: Hospital (2019-2024) & ($ Millions) Figure 12. Idiopathic Pulmonary Fibrosis Treatment in Clinic Figure 13. Global Idiopathic Pulmonary Fibrosis Treatment Market: Clinic (2019-2024) & ($ Millions) Figure 14. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Application in 2023 Figure 15. Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share by Player in 2023 Figure 16. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Regions (2019-2024) Figure 17. Americas Idiopathic Pulmonary Fibrosis Treatment Market Size 2019-2024 ($ Millions) Figure 18. APAC Idiopathic Pulmonary Fibrosis Treatment Market Size 2019-2024 ($ Millions) Figure 19. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size 2019-2024 ($ Millions) Figure 20. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size 2019-2024 ($ Millions) Figure 21. Americas Idiopathic Pulmonary Fibrosis Treatment Value Market Share by Country in 2023 Figure 22. United States Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 23. Canada Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 24. Mexico Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 25. Brazil Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 26. APAC Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Region in 2023 Figure 27. APAC Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Type in 2023 Figure 28. APAC Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Application in 2023 Figure 29. China Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 30. Japan Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 31. Korea Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 32. Southeast Asia Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 33. India Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 34. Australia Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 35. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Country in 2023 Figure 36. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Type (2019-2024) Figure 37. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Application (2019-2024) Figure 38. Germany Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 39. France Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 40. UK Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 41. Italy Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 42. Russia Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 43. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Region (2019-2024) Figure 44. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Type (2019-2024) Figure 45. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share by Application (2019-2024) Figure 46. Egypt Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 47. South Africa Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 48. Israel Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 49. Turkey Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 50. GCC Country Idiopathic Pulmonary Fibrosis Treatment Market Size Growth 2019-2024 ($ Millions) Figure 51. Americas Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 52. APAC Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 53. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 54. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 55. United States Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 56. Canada Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 57. Mexico Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 58. Brazil Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 59. China Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 60. Japan Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 61. Korea Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 62. Southeast Asia Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 63. India Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 64. Australia Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 65. Germany Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 66. France Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 67. UK Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 68. Italy Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 69. Russia Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 70. Spain Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 71. Egypt Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 72. South Africa Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 73. Israel Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 74. Turkey Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 75. GCC Countries Idiopathic Pulmonary Fibrosis Treatment Market Size 2025-2030 ($ Millions) Figure 76. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share Forecast by Type (2025-2030) Figure 77. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Market Share Forecast by Application (2025-2030)
